Search
Faricimab Action Pathway
smpdb.ca/view/SMP0126914Drug actionendothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). … While existing treatments like aflibercept and ranibizumab focus solely on inhibiting VEGF-A, faricimab's unique mechanism involves binding to and depleting both VEGF-A and Ang-2.
Enzymes: Coagulation factor XHeparin Action Pathway
smpdb.ca/view/SMP0123108Drug actionIt accelerates the neutralization of coagulation factors by antithrombin, inhibiting further clotting from occurring as well as any progression of current clots from forming. … It acts by binding antithrombin III that goes on to inactivate factor Xa.
Enzymes: Coagulation factor XCertoparin Action Pathway
smpdb.ca/view/SMP0126157Drug actionCertoparin can interact with herbs and supplements, it is best to avoid those with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. … Certoparin is a heparin with a low molecular weight (LMWH), it prevents and treats venous thromboembolism.
Enzymes: Coagulation factor XEnoxaparin Action Pathway
smpdb.ca/view/SMP0126159Drug actionIt has an immediate onset of action, it binds to antithrombin III, inhibiting factor Xa ceasing the conversion of prothrombin to thrombin. … Enoxaparin can interact with some herbs and supplements, avoid those with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba.
Enzymes: Coagulation factor XDalteparin Action Pathway
smpdb.ca/view/SMP0126160Drug actionDalteparin can interact with herbs and supplements, avoid those with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. … It binds to antithrombin III, inhibiting the formation of Xa and thrombin.
Enzymes: Coagulation factor XNadroparin Action Pathway
smpdb.ca/view/SMP0126171Drug actionIts mechanism of action after subcutaneous administration causes it to bind to antithrombin III and inactive factor Xa. … The inactivation of factor Xa halted the conversion of prothrombin to thrombin and also halts the conversion of fibrinogen.
Enzymes: Coagulation factor XTinzaparin Action Pathway
smpdb.ca/view/SMP0126174Drug actionThis stops the generation of thrombin and the coagulation cascade, it is administered via subcutaneous injection. … It binds to antithrombin III forming a complex that speeds up the inhibition of factor Xa.
Drugs: CalciumEnzymes: Coagulation factor XSunitinib Action Pathway
smpdb.ca/view/SMP0126868Drug actionIts actions encompass inhibiting key signaling pathways by targeting various RTKs, including platelet-derived growth factor receptors (PDGF-R), vascular endothelial growth factor receptors (VEGF-R), and … Sunitinib also affects RET, CSF-1R, and flt3 RTKs.
Enzymes: Coagulation factor XMidostaurin Action Pathway
smpdb.ca/view/SMP0126900Drug actionBy inhibiting these kinases, Midostaurin disrupts signaling cascades that lead to malignancies such as AML and ASM, ultimately inducing apoptosis in leukemia cells and mast cells. … Its mechanism of action involves targeting multiple receptor tyrosine kinases, including protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR, and WT and/or mutant FLT3 tyrosine kinases.
Enzymes: Coagulation factor XRegorafenib Action Pathway
smpdb.ca/view/SMP0126907Drug actionRegorafenib functions as an inhibitor of multiple kinases, playing a role in normal cellular processes and pathological conditions like oncogenesis, tumor angiogenesis, and the maintenance of the tumor … Regorafenib is an oral kinase inhibitor with a broad spectrum of activity. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma.
Enzymes: Coagulation factor X